Accuray has received the Chinese National Medical Products Administration’s (NMPA) approval for its Accuray Precision treatment planning system (TPS), marking a significant milestone for cancer treatment in China.
The Accuray Precision TPS is set to be used alongside the CNNC-Accuray joint venture’s Tomo C radiation therapy system, which offers helical imaging and radiation delivery capabilities.
Go deeper with GlobalData
This combination is poised to offer medical teams a new solution for delivering highly precise and accurate radiotherapy treatments, thereby broadening the scope of care available to cancer patients across China.
Developed to enhance the efficiency and accuracy of treatment plans, the Accuray Precision TPS allows clinicians to swiftly adapt treatment strategies.
It accounts for changes in tumour size, shape and location, as well as shifts in the positioning of organs and healthy tissue. This adaptability significantly bolsters the precision of cancer treatments.
Accuray president and CEO Suzanne Winter said: “With this approval, our China joint venture can begin shipping the Tomo C System to their end customers, an important step forward in helping to address an unmet need for precision radiation therapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“Customers in China who use our organisation’s CyberKnife, Radixact and TomoTherapy Systems are familiar with the Accuray Precision treatment planning system, a powerful, full-featured system that enables clinicians to efficiently generate high-quality radiation therapy treatment plans.
“The availability of the treatment planning solution for the Tomo C System, a domestically made radiation therapy delivery device, will expand our portfolio in China and enhance our access in the regional Type B market.”
The Tomo C platform integrates treatment planning, data management, and precise treatment delivery through patented beam-shaping technology.
Designed to improve outcomes for a range of standard radiation therapy indications such as prostate, breast, lung, and head and neck cancers, the Tomo C system is also adept at managing complex treatments, including total marrow irradiation.
